Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens

Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · see citing works

MGMT: its role in cancer aetiology and cancer therapeutics

Gerson, S. L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1319 · Cited by 817 · see citing works

Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 811 · see citing works

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Hegi, M. E., Diserens, A., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 782 · see citing works

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 779 · see citing works

Clinical Relevance of MGMT in the Treatment of Cancer

Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 429 · see citing works

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

Yip, S. S. F., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 403 · see citing works

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387 · see citing works

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373 · see citing works

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

Giannini, C., Sarkaria, J. N., Saito, A., Uhm, J. H., Galanis, E., Carlson, B. L., Schroeder, M. A., & James, C. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000821 · Cited by 326 · see citing works

Histone modification and the control of heterochromatic gene silencing in Drosophila

Ebert, A., Lein, S., Schotta, G., & Reuter, G. (2006) · Chromosome Research · doi:10.1007/s10577-006-1066-1 · Cited by 209 · see citing works

Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide

Chinot, O. L., Barrié, M., Fuentes, S., Eudes, N., Lancelot, S., Métellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4807 · Cited by 208 · see citing works

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

Everhard, S., Tost, J., abdalaoui, H. E., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle–Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177 · see citing works

MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase–Mediated HOX /Stem Cell Gene Signature

Gaspar, N., Marshall, L. V., Perryman, L., Bax, D. A., Little, S. E., Viana‐Pereira, M., Sharp, S. Y., Vassal, G., Pearson, A. D. J., Reis, R. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1250 · Cited by 163 · see citing works

DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves as a Molecular Mark for Gene Silencing Memory

Raynal, N. J. ‐., Si, J., Taby, R. F., Gharibyan, V., Ahmed, S., Jelı́nek, J., Estecio, M. R., & Issa, J. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3248 · Cited by 133 · see citing works

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule

Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122 · see citing works

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

van Nifterik, K. A., van den Berg, J., van der Meide, W. F., Ameziane, N., Wedekind, L. E., Steenbergen, R. D. M., Leenstra, S., Lafleur, M. V. M., Slotman, B. J., Stalpers, L. J. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605712 · Cited by 116 · see citing works

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome

Wiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114 · see citing works

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications

Zhang, J., Stevens, M. F. G., Laughton, C. A., Madhusudan, S., & Bradshaw, T. D. (2010) · Oncology · doi:10.1159/000306139 · Cited by 110 · see citing works

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53

Naumann, S. C., Roos, W. P., Jöst, E., Belohlavek, C., Lennerz, V., Schmidt, C., Christmann, M., & Kaina, B. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604856 · Cited by 101 · see citing works

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

Kitange, G. J., Carlson, B. L., Mladek, A. C., Decker, P. A., Schroeder, M. A., Wu, W., Grogan, P. T., Giannini, C., Ballman, K. V., Buckner, J. C., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9737-8 · Cited by 97 · see citing works

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Clarke, M. J., Mulligan, E. A., Grogan, P. T., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Curtin, N. J., Lou, Z., Decker, P. A., Wu, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0854 · Cited by 96 · see citing works

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients

Spiegl‐Kreinecker, S., Pirker, C., Filipits, M., Lötsch, D., Buchroithner, J., Pichler, J., Silye, R., Weis, S., Micksche, M., Fischer, J., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop003 · Cited by 88 · see citing works

Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts

Carlson, B. L., Grogan, P. T., Mladek, A. C., Schroeder, M. A., Kitange, G. J., Decker, P. A., Giannini, C., Wu, W., Ballman, K. V., James, C. D., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.026 · Cited by 87 · see citing works

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma

Kong, D., Lee, J.-I., Kim, W. K., Son, M. J., Lim, D. H., Kim, S. H., Park, K., Kim, J. W., Eoh, W., & Nam, D. (2006) · Oncology Reports · doi:10.3892/or.16.5.1117 · Cited by 70 · see citing works

The Essential Role of Histone H3 Lys9 Di-Methylation and MeCP2 Binding in MGMT Silencing with Poor DNA Methylation of the Promoter CpG Island

Zhao, W. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi048 · Cited by 61 · see citing works

Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity

Hirose, Y., Kreklau, E. L., Erickson, L. C., Berger, M. S., & Pieper, R. O. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.3.0591 · Cited by 39 · see citing works

Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells

Papait, R., Magrassi, L., Rigamonti, D., & Cattaneo, E. F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.091 · Cited by 35 · see citing works

MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.

Cahill, D. P., Codd, P. J., Batchelor, T. T., Curry, W. T., & Louis, D. N. (2008) · PubMed · Cited by 30 · see citing works

Efficacy of Temozolomide Is Correlated With 1p Loss and Methylation of the Deoxyribonucleic Acid Repair Gene MGMT in Malignant Gliomas

Ishii, D., Natsume, A., Wakabayashi, T., Hatano, H., Asano, Y., TAKEUCHI, H., Shimato, S., Ito, M., Fujii, M., & Yoshida, J. (2007) · Neurologia medico-chirurgica · doi:10.2176/nmc.47.341 · Cited by 28 · see citing works

Glioblastoma multiforme: Pathogenesis and treatment

Alifieris, C. E., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 815 · see citing works

MGMT testing—the challenges for biomarker-based glioma treatment

Wick, W., Weller, M., van den Bent, M. J., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M. E., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 580 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma

Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1137-5 · Cited by 300 · see citing works

Poised epigenetic states and acquired drug resistance in cancer

Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301 · see citing works

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

Hombach‐Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C. H., Pitz, M. W., Hamaï, A., Siemianowicz, K., Likus, W., Wiecheć, E., Toyota, B. D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 290 · see citing works

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 270 · see citing works

Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p

Wu, P., Cai, J., Chen, Q., Han, B., Meng, X., Li, Y., Li, Z., Wang, R., Lin, L., Duan, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10025-2 · Cited by 181 · see citing works

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169 · see citing works

A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles

Straehla, J. P., Hajal, C., Safford, H. C., Offeddu, G. S., Boehnke, N., Dacoba, T. G., Wyckoff, J. B., Kamm, R. D., & Hammond, P. T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2118697119 · Cited by 157 · see citing works

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

Cabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 141 · see citing works

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135 · see citing works

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme

Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 133 · see citing works

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye‐Agyeman, F., Bakken, K. K., Pokorny, J. L., Schroeder, M. A., Decker, P. A., Cen, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv369 · Cited by 125 · see citing works

Epigenetic modulation of metabolism in glioblastoma

Dong, Z., & Cui, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.002 · Cited by 121 · see citing works

Epigenetic Targeting of Glioblastoma

Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 115 · see citing works

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

Cros, J. F., Hentic, O., Rebours, V., Zappa, M., Gille, N., Théou–Anton, N., Vernerey, D., Maire, F., Lévy, P., Bédossa, P., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0117 · Cited by 110 · see citing works

Mutations in chromatin machinery and pediatric high-grade glioma

Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 93 · see citing works

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex

Guvenc, H., Pavlyukov, M. S., Joshi, K., Kurt, H., Banasavadi‐Siddegowda, Y., Mao, P., Hong, C. S., Yamada, R., Kwon, C., Bhasin, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0647 · Cited by 94 · see citing works

Autophagy as a Potential Therapy for Malignant Glioma

Escamilla-Ramírez, Á., Castillo‐Rodríguez, R. A., Zavala-Vega, S., Jiménez‐Farfán, D., Anaya‐Rubio, I., Briseño, E., Palencia, G., Guevara, P., Cruz-Salgado, A., Sotelo, J., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13070156 · Cited by 91 · see citing works

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Mueller, D. J., Bakken, K. K., Carlson, B. L., Schroeder, M. A., Evans, D. L., Lou, Z., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2588 · Cited by 91 · see citing works

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 91 · see citing works

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

Kreth, S., Limbeck, E., Hinske, L. C., Schütz, S. V., Thon, N., Hoefig, K. P., Egensperger, R., & Kreth, F. W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1081-1 · Cited by 90 · see citing works

Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.

Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S., Varma, A. K., Vandergrift, W. A., Patel, S. J., et al. (2015) · PubMed · Cited by 83 · see citing works

Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets

Aziz‐Bose, R., & Monje, M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000577 · Cited by 79 · see citing works

Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Stacchiotti, S., Tortoreto, M., Bozzi, F., Tamborini, E., Morosi, C., Messina, A., Libertini, M., Palassini, E., Cominetti, D., Negri, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0776 · Cited by 79 · see citing works

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Gupta, S. K., Mladek, A. C., Carlson, B. L., Boakye‐Agyeman, F., Bakken, K. K., Kizilbash, S. H., Schroeder, M. A., Reid, J. M., & Sarkaria, J. N. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3446 · Cited by 79 · see citing works

miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma

Li, Y., Liu, Y., Ren, J. F., Deng, S., Yi, G., Guo, M., Shu, S., Zhao, L., Peng, Y.-P., & Qi, S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2835-3 · Cited by 74 · see citing works

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

Kitange, G. J., Mladek, A. C., Schroeder, M. A., Pokorny, J. C., Carlson, B. L., Zhang, Y., Nair, A., Lee, J., Yan, H., Decker, P. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.045 · Cited by 73 · see citing works

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 71 · see citing works

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

Banelli, B., Daga, A., Forlani, A., Allemanni, G., Marubbi, D., Pistillo, M. P., Profumo, A., & Romani, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16820 · Cited by 71 · see citing works

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

Romani, M., Daga, A., Forlani, A., Pistillo, M. P., & Banelli, B. (2019) · Cancers · doi:10.3390/cancers11060878 · Cited by 71 · see citing works

Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Li, F., Chen, S., Yu, J., Gao, Z., Sun, Z., Yang, Y., Long, T., Zhang, C., Li, Y., Pan, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.553 · Cited by 69 · see citing works

ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells

Nadkarni, A., Shrivastav, M., Mladek, A. C., Schwingler, P. M., Grogan, P. T., Chen, J., & Sarkaria, J. N. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0979-0 · Cited by 68 · see citing works

Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma

Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 66 · see citing works

Immunohistochemical profiles of I DH 1, MGMT and P 53: Practical significance for prognostication of patients with diffuse gliomas

Ogura, R., Tsukamoto, Y., Natsumeda, M., Isogawa, M., Aoki, H., Kobayashi, T., Yoshida, S., Okamoto, K., Takahashi, H., Fujii, Y., et al. (2015) · Neuropathology · doi:10.1111/neup.12196 · Cited by 64 · see citing works

Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells

Zhao, J., Jin, W., Yi, K., Wang, Q., Zhou, J., Tan, Y., Xu, C., Xiao, M., Hong, B., Xu, F., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105764 · Cited by 64 · see citing works

Triacetin‐based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma

Tsen, A. R., Long, P. M., Driscoll, H. E., Davies, M. T., Teasdale, B., Penar, P. L., Pendlebury, W. W., Spees, J. L., Lawler, S. E., Viapiano, M. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28465 · Cited by 62 · see citing works

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

Teraiya, M., Perreault, H., & Chen, V. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166207 · Cited by 63 · see citing works

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives

Shaw, R., Basu, M., Karmakar, S., & Ghosh, M. K. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119673 · Cited by 62 · see citing works

Acetate as a Metabolic and Epigenetic Modifier of Cancer Therapy

Jaworski, D. M., Namboodiri, A. M. A., & Moffett, J. R. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25305 · Cited by 63 · see citing works

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma

Nie, E., Miao, F., Jin, X., Wu, W., Zhou, X., Zeng, A., Yu, T., Zhi, T., Shi, Z., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0596-2 · Cited by 58 · see citing works

Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle

Ruscio, V. D., Baldo, G. D., Fabozzi, F., Vinci, M., Cacchione, A., de Billy, E., Megaro, G., Carai, A., & Mastronuzzi, A. (2022) · Diagnostics · doi:10.3390/diagnostics12092064 · Cited by 57 · see citing works

Understanding and Targeting Alkylator Resistance in Glioblastoma

Wick, W., & Platten, M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0918 · Cited by 51 · see citing works

A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance

Karve, A. S., Desai, J. M., Gadgil, S. N., Dave, N., Wise-Draper, T. M., Gudelsky, G. A., Phoenix, T. N., Dasgupta, B., Yogendran, L., Sengupta, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063217 · Cited by 49 · see citing works

Mesenchymal Stem Cells Cancel Azoxymethane-Induced Tumor Initiation

Nasuno, M., Arimura, Y., Nagaishi, K., Isshiki, H., Onodera, K., Nakagaki, S., Watanabe, S., Idogawa, M., Yamashita, K., Naishiro, Y., et al. (2013) · Stem Cells · doi:10.1002/stem.1594 · Cited by 49 · see citing works

RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance

Li, J., Song, C., Gu, J., Li, C., Zang, W., Shi, L., Chen, L., Zhu, L., Zhou, M., Wang, T., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216078 · Cited by 47 · see citing works

Epigenetic alternations and cancer chemotherapy response

Lv, J., Hu, L., Zhuo, W., Zhang, C., Zhou, H., & Fan, L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2951-0 · Cited by 46 · see citing works

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines

Anderson, J. C., Duarte, C. W., Welaya, K. Y., Rohrbach, T. D., Bredel, M., Yang, E. S.-H., Choradia, N., Thottassery, J. V., Gillespie, G. Y., Bonner, J. A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.010 · Cited by 45 · see citing works

Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments

Martínez‐Useros, J., Martin-Galan, M., Florez-Cespedes, M., & García‐Foncillas, J. (2021) · Cancers · doi:10.3390/cancers13133209 · Cited by 44 · see citing works

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance

Hersh, D. S., Harder, B. G., Roos, A., Peng, S., Heath, J. E., Legesse, T. B., Kim, A. J., Woodworth, G. F., Tran, N. L., & Winkles, J. A. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy063 · Cited by 43 · see citing works

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase

Poon, W. S., Woo, P. M., Li, Y., Chan, A. Y., Ng, S. P., Loong, H. H.-F., Chan, D. M., & Wong, G. K. C. (2019) · Glioma · doi:10.4103/glioma.glioma_3_19 · Cited by 44 · see citing works

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways

Sampson, V. B., Vetter, N. S., Kamara, D. F., Collier, A. B., Gresh, R. C., & Kolb, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142704 · Cited by 42 · see citing works

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas

Gonçalves, R. M., Agnes, J. P., Delgobo, M., de Souza, P. O., Thomé, M. P. M., Heimfarth, L., Lenz, G., Moreira, J. C. F., & Zanotto‐Filho, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.015 · Cited by 42 · see citing works

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells

Harder, B. G., Peng, S., Sereduk, C., Sodoma, A. M., Kitange, G. J., Loftus, J. C., Sarkaria, J. N., & Tran, N. L. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0116-z · Cited by 41 · see citing works

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0600 · Cited by 39 · see citing works

Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state

Steed, T., Treiber, J. M., Taha, B. R., Engin, H. B., Carter, H. K., Patel, K. S., Dale, A. M., Carter, B. S., & Chen, C. C. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03550-4 · Cited by 38 · see citing works

Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis

Wei, B., Wang, L., Du, C., Hu, G., Wang, L., Jin, Y., & Kong, D. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3094 · Cited by 37 · see citing works

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

Laverty, D. J., Gupta, S. K., Bradshaw, G. A., Hunter, A. S., Carlson, B. L., Calmo, N. M., Chen, J., Tian, S., Sarkaria, J. N., & Nagel, Z. D. (2024) · Nature Communications · doi:10.1038/s41467-024-49316-8 · Cited by 39 · see citing works

Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients

Chen, Y., Ho, H., Lin, S., Ho, T. D.-H., & Hsu, C. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy008 · Cited by 36 · see citing works

Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme

Angom, R. S., Mondal, S. K., Wang, F., Madamsetty, V. S., Wang, E., Dutta, S. K., Gulani, Y., Sarabia-Estrada, R., Sarkaria, J. N., Quiñones‐Hinojosa, A., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01462-1 · Cited by 36 · see citing works

Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?

Burko, P., D’Amico, G., Miltykh, I. S., Scalia, F., de Macario, E. C., Macario, A. J. L., Giglia, G., Cappello, F., & Bavisotto, C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054883 · Cited by 35 · see citing works

Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas

Chiang, M., Chou, P., Wang, W., Sze, C., & Chang, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00043 · Cited by 35 · see citing works

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study

Shen, D., Liu, T., Lin, Q., Lu, X., Wang, Q., Lin, F., & Mao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107558 · Cited by 32 · see citing works

Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat

Stephanie Huang, R. (2013) · Chemotherapy Open access · doi:10.4172/2167-7700.1000111 · Cited by 30 · see citing works

Targeting of histone deacetylases in brain tumors

Ecker, J., Witt, O., & Milde, T. (2013) · CNS Oncology · doi:10.2217/cns.13.24 · Cited by 30 · see citing works

High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

Arrizabalaga, O., Moreno‐Cugnon, L., Auzmendi-Iriarte, J., Aldaz, P., de Cáceres, I. I., Garros-Regulez, L., Moncho-Amor, V., Torres-Bayona, S., Pernía, O., Pintado‐Berninches, L., et al. (2017) · Oncogenesis · doi:10.1038/s41389-017-0003-9 · Cited by 31 · see citing works

Contemporary murine models in preclinical astrocytoma drug development

McNeill, R. S., Vitucci, M., Wu, J., & Miller, C. R. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou288 · Cited by 29 · see citing works

Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas

Vanan, M., Underhill, D. A., & Eisenstat, D. D. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0514-2 · Cited by 29 · see citing works

Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA

Laws, M. T., Bonomi, R. E., Kamal, S., Gelovani, D. J., Llaniguez, J. T., Potukutchi, S., Lu, X., Mangner, T. J., & Gelovani, J. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40054-2 · Cited by 29 · see citing works

RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Mladek, A. C., Yan, H., Tian, S., Decker, P. A., Burgenske, D. M., Bakken, K. K., Hu, Z., He, L., Connors, M. A., Carlson, B. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac051 · Cited by 29 · see citing works

Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity

Riva, G., Butta, V., Cilibrasi, C., Baronchelli, S., Redaelli, S., Dalprà, L., Lavitrano, M., & Bentivegna, A. (2016) · Oncology Reports · doi:10.3892/or.2016.4665 · Cited by 29 · see citing works

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells

Nagel, Z. D., Beharry, A. A., Mazzucato, P., Kitange, G. J., Sarkaria, J. N., Kool, E. T., & Samson, L. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208341 · Cited by 28 · see citing works

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma

Yang, E., Hong, B., Wang, Y., Wang, Q., Zhao, J., Cui, X., Wu, Y., Yang, S., Su, D., Liu, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216812 · Cited by 27 · see citing works

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

Hsu, C., Ho, H., Lin, S., Chang‐Chien, Y., Chen, M.-H., Hsu, S. P. C., Yen, Y., Guo, W.-Y., & Ho, D. M. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1701-1 · Cited by 27 · see citing works

Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes

Li, H., Sun, C., He, M., Yin, L.-C., Du, H.-G., & Zhang, J. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.055 · Cited by 27 · see citing works

Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Ramirez, Y. P., Mladek, A. C., Phillips, R. M., Gynther, M., Rautio, J., Ross, A. H., Wheelhouse, R. T., & Sakaria, J. N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0113 · Cited by 26 · see citing works

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

Gong, L., Yin, Y., Cheng, C., Wan, Q., Xia, D., Wang, M., Pu, Z., Zhang, B., & Zou, J. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01230-y · Cited by 25 · see citing works

Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide

Čuperlović‐Culf, M., Touaibia, M., St‐Cœur, P., Poitras, J., Morin, P., & Culf, A. S. (2014) · Metabolites · doi:10.3390/metabo4030807 · Cited by 24 · see citing works

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future

Huang, W., Hao, Z., Mao, F., & Guo, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911876 · Cited by 23 · see citing works

Role of miRNAs in Treatment Response and Toxicity of Childhood Acute Lymphoblastic Leukemia

Umerez, M., García‐Obregón, S., Martín‐Guerrero, I., Astigarraga, I., Gutiérrez-Camino, Á., & García‐Orad, Á. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0164 · Cited by 22 · see citing works

Critical appraisal of MGMT in digestive NET treated with alkylating agents

de Mestier, L., Couvelard, A., Blažević, A., Hentic, O., de Herder, W. W., Rebours, V., Paradis, V., Ruszniewski, P. B., Hofland, L. J., & Cros, J. F. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0227 · Cited by 22 · see citing works

Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies

Nguyen, T. T. T., Greene, L. A., Mnatsakanyan, H., & Badr, C. E. (2024) · Biomedicines · doi:10.3390/biomedicines12061376 · Cited by 21 · see citing works

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma

Hsu, C., Ho, H., Lin, S., Ho, T. D.-H., & Ho, D. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186430 · Cited by 21 · see citing works

Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology

Sesé, B., Ensenyat-Méndez, M., Íñiguez-Muñoz, S., Llinàs‐Arias, P., & Marzese, D. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01139-w · Cited by 20 · see citing works

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma

Daniel, P. M., Meehan, B., Sabri, S., Jamali, F., Sarkaria, J. N., Choi, D., Garnier, D., Kitange, G. J., Glennon, K. I., Paccard, A., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac076 · Cited by 21 · see citing works

An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases

Stackhouse, C. T., Anderson, J. C., Yue, Z., Nguyen, T. M., Eustace, N. J., Langford, C. P., Wang, J., Rowland, J. R., Xing, C., Mikhail, F. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.148717 · Cited by 23 · see citing works

Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients

Hsu, C., Ho, H., Lin, S., Chen, M., Hsu, S. P., Yen, Y., Guo, W., & Ho, D. M. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000331 · Cited by 21 · see citing works

Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase

Rao, V., Kumar, G., Vibhavari, R. J. A., Nandakumar, K., Thorat, N. D., Chamallamudi, M. R., & Kumar, N. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220404180944 · Cited by 20 · see citing works

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide

Ensign, S. P. F., Roos, A., Mathews, I. T., Dhruv, H., Tuncali, S., Sarkaria, J. N., Symons, M. H., Loftus, J. C., Berens, M. E., & Tran, N. L. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0183 · Cited by 19 · see citing works

Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma

Al‐Holou, W. N., Wang, H., Ravikumar, V., Shankar, S., Oneka, M. D., Fehmi, Z., Verhaak, R. G. W., Kim, H., Pratt, D. W., Camelo-Piragua, S. I., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2022.100872 · Cited by 20 · see citing works

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

Everix, L., Seane, E. N., Ebenhan, T., Goethals, I., & Bolcaen, J. (2023) · Pharmaceuticals · doi:10.3390/ph16020227 · Cited by 19 · see citing works

Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells

Zhang, L., Yan, Y., Jiang, Y., Qian, J., Jiang, L., Hu, G., Lu, Y., & Luo, C. (2017) · Oncology Letters · doi:10.3892/ol.2017.6722 · Cited by 19 · see citing works

Effects of Culture Condition on Epigenomic Profiles of Brain Tumor Cells

Cox, M. C., Deng, C., Naler, L. B., Lu, C., & Verbridge, S. S. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00161 · Cited by 18 · see citing works

Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)

Yousefi, Y., Nejati, R., Eslahi, A., Alizadeh, F. L., Farrokhi, S., Asoodeh, A., & Mojarrad, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04708-0 · Cited by 17 · see citing works

MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

Xu, J., Lou, X., Wang, F., Zhang, W., Xu, X., Ye, Z., Zhuo, Q., Wang, Y., Jing, D., Fan, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202308417 · Cited by 17 · see citing works

Deep learning MRI signature to predict survival and treatment benefit from temozolomide in IDH-wildtype glioblastoma

You, H., Zhao, Y., Sun, Q., Wu, W., Lv, X., Chen, Y., Zhang, H., & Li, Z. (2023) · Displays · doi:10.1016/j.displa.2023.102399 · Cited by 15 · see citing works

Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics

Singh, S., Nema, R., Banerjee, M., & Kushwah, A. S. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002335 · Cited by 14 · see citing works

Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies

Liu, G., Qiu, Y., Zhang, P., Chen, Z., Chen, S., Huang, W., Wang, B., Yu, X., & Guo, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091762 · Cited by 14 · see citing works

MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types

Bacolod, M. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203111620 · Cited by 13 · see citing works

Abstract 5905: Sp1 acetylation associates with stemness characteristics in temozolomide-resistant glioblastoma

Chuang, J., Hsu, C., Chang, K., & Chang, W. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5905 · Cited by 5 · see citing works

GENE-20. A NOVEL K-M ENHANCER REGULATES TEMOZOLOMIDE RESISTANCE AND TUMOR GROWTH IN GLIOBLASTOMA

Chen, X., Zhang, M., Gan, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Zhang, Z., & Sarkaria, J. N. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy148.446

Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data

Ye, L., Gu, L., Wang, Y., Xing, H., Li, P., Guo, X.-P., Wang, Y., & Ma, W. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14649 · Cited by 14 · see citing works

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaPreprint

Aksu, F., Cevatemre, B., Degirmenci, N. P., Kala, E. Y., Uçku, D., Philpott, M., Cribbs, A. P., Dunford, J. E., Oppermann, U. C. T., Açılan, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723296

Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Li, F., Chen, S., Yu, J., Gao, Z., Sun, Z., Yang, Y., Long, T., Zhang, C., Li, Y., Pan, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.553 · Cited by 69 · see citing works